case_images: PMC11021721_01
case_images: Evolution of inflammation throughout the clinical course. Timeline of hemoadsorption intervention: (A) 1st CytoSorb - 3 h-treatment on the first day of hospitalization, just before vvECMO commenced, therapeutic; (B) 2nd CytoSorb - 12 h-treatment parallel to vvECMO start, therapeutic; (C) 3rd CytoSorb - 12 h treatment immediately after weaning from vvECMO (decannulation), prophylactic.
case_images: fmed-11-1341156-g001.jpg
case_images: PMC11021721_01_fmed-11-1341156-g001.jpg
case_images: fig1
case_images: Inc., Princeton, NJ, USA), integrated into pre-hemofilter mode while administering unfractionated heparin for anticoagulation. Inflammation parameters were initially assessed from the patient's serum before and after the therapeutic application of the adsorber on the first day, followed by daily monitoring thereafter (Figure 1). The need for a vasopressor (norepinephrine) terminated on day 4 of the ICU treatment (Figures 1, 2; Table 1). Acid-base balance was reestablished through the normalization of lactate levels, and inflammatory biomarkers IL-6 and C-reactive protein (CRP) (Figures 1, 2; Table 1). During the following days, the levels of inflammatory parameters remained within normal range, indicating the absence of systemic inflammation (Figure 1; Table 1).
case_images: Evolution of hemodynamic parameters throughout the clinical course. Timeline of hemoadsorption intervention: (A) 1st CytoSorb - 3 h-treatment on the first day of hospitalization, just before vvECMO commenced, therapeutic; (B) 2nd CytoSorb - 12 h-treatment parallel to vvECMO start, therapeutic; (C) 3rd CytoSorb - 12 h treatment immediately after weaning from vvECMO (decannulation), prophylactic.
case_images: fmed-11-1341156-g002.jpg
case_images: PMC11021721_01_fmed-11-1341156-g002.jpg
case_images: fig2
case_images: The need for a vasopressor (norepinephrine) terminated on day 4 of the ICU treatment (Figures 1, 2; Table 1). Acid-base balance was reestablished through the normalization of lactate levels, and inflammatory biomarkers IL-6 and C-reactive protein (CRP) (Figures 1, 2; Table 1).